Ripizol Indications/Uses

Schizophrenia: ARIPIPRAZOLE is indicated for the treatment of schizophrenia. The efficacy of ARIPIPRAZOLE was established in 4-6 week in adults and 6-week in adolescents (13-17 years).
Bipolar I Disorder: Acute Treatment of Manic and Mixed Episodes: ARIPIPRAZOLE is indicated for the acute treatment of manic and mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate. Efficacy as monotherapy was established in 3-week in adults and 4-week in pediatric patients (10-17 years). Efficacy as adjunctive therapy was established in 6-week in adults.
Maintenance Treatment of Bipolar I Disorder: ARIPIPRAZOLE is indicated for the maintenance treatment of Bipolar I Disorder, both as monotherapy and as an adjunct to lithium or valproate.
Adjunctive Treatment of Major Depressive Disorder: ARIPIPRAZOLE is indicated for use as a therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was established in 6-week in adults with MDD who had an inadequate response to antidepressant therapy during the current episode.
Irritability Associated with Autistic Disorder: ARIPIPRAZOLE is indicated for the treatment of irritability associated with autistic disorder. Efficacy was established in 8-week in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).
Tourette's Disorder: ARIPIPRAZOLE is indicated for the treatment of Tourette's disorder.
Special Considerations in Treating Pediatric Schizophrenia, Bipolar I Disorder, and Irritability Associated with Autistic disorder: Psychiatric disorder in children and adolescent are often serious mental disorder with variable symptom profiles that are not always congruent with adult diagnostic criteria. It is recommended that psychotropic medication therapy for pediatric patients only be initiated after a thorough diagnostic evaluation has been conducted and careful consideration given to the risks associated with medication treatment. Medication treatment for pediatric patients with schizophrenia, bipolar I disorder, and irritability associated with autistic disorder is indicated as part of a total treatment program that often includes psychological, educational, and social interventions.